Published on in Vol 11, No 12 (2022): December
Preprints (earlier versions) of this paper are
available at
https://preprints.jmir.org/preprint/43741, first published
.
1 Regional Medical Affairs, Pfizer Corporation Hong Kong Limited, Hong Kong, China (Hong Kong)
2 Executive Office, Transform Medical Communications Limited, Wanganui, New Zealand
*these authors contributed equally